Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

39.07 +1.55 (+4.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 242,689
Open 38.80
Bid (Size) 38.99 (1)
Ask (Size) 39.07 (2)
Prev. Close 37.52
Today's Range 37.50 - 39.40
52wk Range 11.17 - 40.50
Shares Outstanding 98,935,025
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+225.6%
+225.6%
1 Month
+56.9%
+56.9%
3 Month
+70.4%
+70.4%
6 Month
+181.3%
+181.3%
1 Year
+204.5%
+204.5%

More News

Read More
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For May 15, 2025
Via Benzinga
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of
From Palvella Therapeutics Inc.
Via GlobeNewswire
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Palvella Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
From Palvella Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For March 31, 2025
Via Benzinga
Pavella - Undiscovered Biotechnology Stock
Via Talk Markets
Topics Stocks / Equities
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
From Palvella Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Palvella Therapeutics, Inc. - Common Stock publicly traded?
Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?
Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?
The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market
What is the current price of Palvella Therapeutics, Inc. - Common Stock?
The current price of Palvella Therapeutics, Inc. - Common Stock is 39.07
When was Palvella Therapeutics, Inc. - Common Stock last traded?
The last trade of Palvella Therapeutics, Inc. - Common Stock was at 08/06/25 04:00 PM ET
What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?
The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 3.87B
How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?
Palvella Therapeutics, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.